

ABBOTT LABORATORIES  
Form 3  
September 26, 2013

**FORM 3** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |                                      |  |  |
|---|---------|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person * |         | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol |  |
| Â Contreras Jaime                         |         | (Month/Day/Year)                     | ABBOTT LABORATORIES [ABT]                          |  |
| (Last)                                    | (First) | 09/16/2013                           |  |  |
| 100 ABBOTT PARK ROAD                      |         |                                      | 4. Relationship of Reporting Person(s) to Issuer   | 5. If Amendment, Date Original Filed(Month/Day/Year)                   |
| (Street)                                  |         |                                      | (Check all applicable)                             |  |
| ABBOTT PARK,Â ILÂ 60064                   |         |                                      | <input type="checkbox"/> Director                  | 6. Individual or Joint/Group Filing(Check Applicable Line)             |
| (City)                                    | (State) | (Zip)                                | <input checked="" type="checkbox"/> Officer        | <input checked="" type="checkbox"/> Form filed by One Reporting Person |
|   |         |                                      | (give title below)                                 | <input type="checkbox"/> Form filed by More than One Reporting Person  |
|   |         |                                      | Senior Vice President                              |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common shares without par value | 23,733  | D  | Â   |
| Common shares without par value | 20 <sup>(1)</sup>                                     | I  | Profit Sharing Trust                                  |
| Common shares without par value | 63,903 <sup>(2)</sup>                                 | I  | Jaime Contreras Marvan 2006 Living Trust              |
| Common shares without par value | 2,066 <sup>(3)</sup>                                  | I  | By spouse   |
| Common shares without par value | 16 <sup>(4)</sup>                                     | I  | Profit Sharing Trust (by spouse)                      |
| Common shares without par value | 12,081 <sup>(5)</sup>                                 | I  | Living Trust (by spouse)                              |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

Edgar Filing: ABBOTT LABORATORIES - Form 3

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 3. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 4) |                                  | 4.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 5.<br>Ownership<br>Form of<br>Derivative<br>Security:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) | 6. Nature of Indirect<br>Beneficial<br>Ownership<br>(Instr. 5) |
|---|--|--------------------|--|----------------------------------|---|---|--|
|   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount or<br>Number of<br>Shares |   |   |  |
| Option (right to buy) <u>(6)</u>              | 02/15/2009   | 02/14/2018         | Common<br>shares   | 11,300                           | \$ 26.7   | D   | Â  |
| Option (right to buy) <u>(6)</u>              | 02/15/2010   | 02/14/2018         | Common<br>shares   | 11,300                           | \$ 26.7   | D   | Â  |
| Option (right to buy) <u>(6)</u>              | 02/15/2011   | 02/14/2018         | Common<br>shares   | 11,300                           | \$ 26.7   | D   | Â  |
| Option (right to buy) <u>(6)</u>              | 02/20/2010   | 02/19/2019         | Common<br>shares   | 5,900                            | \$ 26.02  | D   | Â  |
| Option (right to buy) <u>(6)</u>              | 02/20/2011   | 02/19/2019         | Common<br>shares   | 5,900                            | \$ 26.02  | D   | Â  |
| Option (right to buy) <u>(6)</u>              | 02/20/2012   | 02/19/2019         | Common<br>shares   | 5,900                            | \$ 26.02  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/19/2011   | 02/18/2020         | Common<br>shares   | 4,467                            | \$ 26.19  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/19/2012   | 02/18/2020         | Common<br>shares   | 4,466                            | \$ 26.19  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/19/2013   | 02/18/2020         | Common<br>shares   | 4,467                            | \$ 26.19  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/18/2012   | 02/17/2021         | Common<br>shares   | 5,767                            | \$ 22.39  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/18/2013   | 02/17/2021         | Common<br>shares   | 5,766                            | \$ 22.39  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/18/2014   | 02/17/2021         | Common<br>shares   | 5,767                            | \$ 22.39  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/17/2013   | 02/16/2022         | Common<br>shares   | 7,334                            | \$ 27.03  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/17/2014   | 02/16/2022         | Common<br>shares   | 7,333                            | \$ 27.03  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/17/2015   | 02/16/2022         | Common<br>shares   | 7,333                            | \$ 27.03  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 07/15/2013   | 02/19/2014         | Common<br>shares   | 21,108                           | \$ 33.37  | D   | Â  |
| Option (right to buy) <u>(7)</u>              | 02/15/2014   | 02/14/2023         |  | 19,934                           | \$ 34.94  | D   | Â  |

Edgar Filing: ABBOTT LABORATORIES - Form 3

|  |            |            | Common shares |        |          |   |           |
|--|------------|------------|---------------|--------|----------|---|-----------|
| Option (right to buy) <sup>(7)</sup>                   | 02/15/2015 | 02/14/2023 | Common shares | 19,933 | \$ 34.94 | D | Â         |
| Option (right to buy) <sup>(7)</sup>                   | 02/15/2016 | 02/14/2023 | Common shares | 19,933 | \$ 34.94 | D | Â         |
| Option (right to buy) <sup>(7)</sup>                   | 08/20/2013 | 02/19/2014 | Common shares | 1,545  | \$ 35.08 | D | Â         |
| Option (right to buy) <sup>(3)</sup><br><sup>(6)</sup> | 07/20/2008 | 07/19/2017 | Common shares | 1,034  | \$ 25.76 | I | By spouse |
| Option (right to buy) <sup>(3)</sup><br><sup>(6)</sup> | 07/20/2009 | 07/19/2017 | Common shares | 1,033  | \$ 25.76 | I | By spouse |
| Option (right to buy) <sup>(3)</sup><br><sup>(6)</sup> | 07/20/2010 | 07/19/2017 | Common shares | 1,033  | \$ 25.76 | I | By spouse |
| Option (right to buy) <sup>(3)</sup><br><sup>(6)</sup> | 02/15/2009 | 02/14/2018 | Common shares | 1,067  | \$ 26.7  | I | By spouse |
| Option (right to buy) <sup>(3)</sup><br><sup>(6)</sup> | 02/15/2010 | 02/14/2018 | Common shares | 1,067  | \$ 26.7  | I | By spouse |
| Option (right to buy) <sup>(3)</sup><br><sup>(6)</sup> | 02/15/2011 | 02/14/2018 | Common shares | 1,066  | \$ 26.7  | I | By spouse |
| Option (right to buy) <sup>(3)</sup><br><sup>(7)</sup> | 08/20/2013 | 02/19/2014 | Common shares | 2,715  | \$ 35.08 | I | By spouse |

## Reporting Owners

| Reporting Owner Name / Address                                   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| Contreras Jaime<br>100 ABBOTT PARK ROAD<br>ABBOTT PARK, IL 60064 | Â             | Â         | Â Senior Vice President | Â     |

## Signatures

John A. Berry, by power of attorney for Jaime Contreras 09/26/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Balance in the Abbott Laboratories Stock Retirement Trust as of 9/16/13.
- (2) Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.
- (3) The reporting person disclaims beneficial ownership of all securities held by his spouse.

## Edgar Filing: ABBOTT LABORATORIES - Form 3

- (4) Balance held by spouse in the Abbott Laboratories Stock Retirement Trust as of 9/16/13. The reporting person disclaims beneficial ownership of these securities.
- (5) Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities.
- (6) Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
- (7) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.